Antithrombotic Drugs-Pharmacology and Perspectives.

Antithrombotic Drugs-Pharmacology and Perspectives. Adv Exp Med Biol. 2020;1177:101-131 Authors: Li T, Yuan D, Yuan J Abstract Thrombosis, the localized clotting of blood that affects arterial or venous circulation, is one of the leading causes of death worldwide. Arterial thrombosis is commonly initiated by vascular endothelial injury, while venous thrombosis mainly stems from blood stasis. Despite these differences, platelet adhesion, activation and aggregation, and fibrin formation as a result of coagulation constitute the fundamental processes of thrombus formation. Antithrombotic drugs permitted on the clinical currently can dramatically reduce major adverse cardiovascular events; however, they can also increase the bleeding risk. Discovery of antithrombotic drugs that can effectively prevent thrombosis while sparing bleeding side effects remains unmet medical need. In this chapter, we provide an overview on the pathophysiology of thrombosis, followed by introduction of each class of antithrombotic drugs including their pharmacology, clinical applications and limitations. Practical challenges and future perspectives of antithrombotic drugs are discussed in the last part of this chapter. PMID: 32246445 [PubMed - as supplied by publisher]
Source: Advances in Experimental Medicine and Biology - Category: Research Tags: Adv Exp Med Biol Source Type: research

Related Links:

Ventricular assist devices (VADs) are an increasingly common therapy for end-stage heart failure across all ages as a bridge to recovery or transplant and more recently as destination therapy. With increasing experience and difficulties with establishing therapeutic heparin levels, we have begun to explore the effectiveness of direct thrombin inhibitors in this patient population. This is a retrospective review of all long-term VAD patients, both adult and pediatric, who were anticoagulated with bivalirudin between January 2009 and January 2016. The starting dose was 0.3 mg/kg/hr, and dose was titrated for a goal pa...
Source: ASAIO Journal - Category: Medical Devices Tags: Pediatric Circulatory Support Source Type: research
Authors: Becattini C, Cimini LA Abstract INTRODUCTION: Anticoagulant treatment reduces recurrent venous thromboembolism (VTE) by about 90% after index pulmonary embolism. Whether anticoagulant treatment also reduces mortality in these patients remains to be defined. The main counterbalance for life long anticoagulation is the risk for anticoagulants-associated bleeding. AREAS COVERED: Literature search was performed in PubMed and Embase. We aimed to review the risk for recurrent VTE over time after discontinuation of anticoagulants and the risks for bleeding and for fatal bleeding over time during anticoagulant...
Source: Expert Review of Hematology - Category: Hematology Tags: Expert Rev Hematol Source Type: research
Abstract An understanding of reversal strategies alone is important to safely and effectively care for patients in cases of bleeding or invasive procedures. The recent diversification in the number of licensed anticoagulants makes an understanding of drug-specific reversal strategies essential. Intravenous or oral vitamin K can reverse the effect of vitamin K antagonists (VKAs) within 12 to 48 hours and is indicated for any bleeding or an international normalized ratio>10 or 4.5 to 10 in patients with additional risk factors for bleeding. Furthermore, an additional administration of prothrombin complex c...
Source: Hamostaseologie - Category: Hematology Authors: Tags: Hamostaseologie Source Type: research
Extended direct oral anticoagulant (DOAC) therapy may be required for patients with a venous thromboembolism (VTE); thus, DOAC adherence may impact the risk of recurrent VTE or bleeding.
Source: Thrombosis Research - Category: Hematology Authors: Tags: Full Length Article Source Type: research
Conclusions:Prasugrel and ticagrelor reduced ischemic events and increased bleeding in comparison to clopidogrel. A significant mortality reduction was observed with ticagrelor only. There was no efficacy and safety difference between prasugrel and ticagrelor. PROSPERO ID: CRD42019155648. PMID: 32468837 [PubMed - as supplied by publisher]
Source: Circulation - Category: Cardiology Authors: Tags: Circulation Source Type: research
Conditions:   COVID;   Thrombosis;   Bleeding;   Anticoagulation Intervention:   Other: Non-interventional Sponsor:   Imperial College London Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Acute pulmonary embolism (PE) is associated with high in-hospital morbidity and mortality, both via cardiorespiratory decompensation and the bleeding complications of treatment. Thrombolytic therapy can be life-saving in those with high-risk PE, but requires careful patient selection. Patients with PE and systemic arterial hypotension ( “massive PE”) should receive thrombolytic therapy unless severe contraindications are present. Patients with PE and right ventricular dysfunction/injury, but without hypotension (“submassive PE”), should be considered for thrombolysis on a case-by-case basis, conside...
Source: Critical Care Clinics - Category: Intensive Care Authors: Source Type: research
Patients with hemophilia are at a high risk of developing arthropathy and so are more likely to require surgery during their lifetime; in particular, major orthopedic surgery [1]. The management of patients with hemophilia undergoing surgery has additional considerations, as they are more likely to experience excessive or prolonged bleeding and associated complications, compared with patients without hemophilia [2].
Source: Thrombosis Research - Category: Hematology Authors: Tags: Letter to the Editors-in-Chief Source Type: research
Classification of the X-linked recessive bleeding disorder Hemophilia A (HA) is based on residual Factor VIII activity level (FVIII:C) that largely correlates with bleeding severity. Understanding the underlying basis for bleeding phenotypes differing from those predicted by FVIII:C should refine classification of patients, clarify genotype-phenotype correlations, and improve clinical management of persons with HA.
Source: Thrombosis Research - Category: Hematology Authors: Tags: Letter to the Editors-in-Chief Source Type: research
Hemophilia A is a bleeding disorder due to the deficiency of coagulation factor VIII (FVIII). According to resident FVIII activity, the disease was divided into mild type (FVIII:c  > 5 IU/dL), moderate type (FVIII:c 1–5 IU/dL) and severe type (FVIII:c 
Source: Thrombosis Research - Category: Hematology Authors: Tags: Letter to Editors-in-Chief Source Type: research
More News: Biology | Bleeding | Cardiology | Cardiovascular | Drugs & Pharmacology | Heart | Research | Thrombosis